ATryn approved for anticoagulation

The FDA has approved ATryn (antithrombin [recombinant], from GTC Biotherapeutics and Ovation Pharmaceuticals), an anticoagulant for the prevention of peri-operative and peri-partum blood clots in patients with hereditary antithrombin (AT) deficiency. ATryn is a therapeutic protein derived from the milk of goats that have been genetically engineered by introducing a segment of DNA into their genes (called a recombinant DNA or rDNA construct) with instructions for the goat to produce human antithrombin in its milk.  

ATryn is expected to be available in the second quarter of 2009.  

For more information call (866) 402-8520 or visit www.ovationpharma.com.